44 results
8-K
ATXI
Avenue Therapeutics Inc
13 Oct 20
Avenue Therapeutics Receives Complete Response Letter from the FDA for IV Tramadol
6:10am
supervised health care setting. A copy of such press release is being furnished as Exhibit 99.1 to this report.
Item 9.01.
Financial Statements and Exhibits
8-K
ATXI
Avenue Therapeutics Inc
11 Dec 19
Avenue Therapeutics Announces Submission of New Drug Application for IV Tramadol
9:00am
tramadol for the management of moderate to moderately severe pain in adults in a medically supervised health care setting. A copy of such press release
8-K
ATXI
Avenue Therapeutics Inc
13 Feb 20
Avenue Therapeutics Announces New Drug Application for IV Tramadol Accepted for Review by FDA
9:15am
Application for IV tramadol for the management of moderate to moderately severe pain in adults in a medically supervised health care setting. A copy
8-K
EX-99.1
ATXI
Avenue Therapeutics Inc
11 Dec 19
Avenue Therapeutics Announces Submission of New Drug Application for IV Tramadol
9:00am
severe pain in adults in a medically supervised health care setting.
The NDA for IV tramadol is based on positive results from two pivotal Phase 3
CORRESP
ATXI
Avenue Therapeutics Inc
2 May 18
Correspondence with SEC
12:00am
2, 2018
Ms. Suzanne Hayes
Assistant Director
Office of Health Care and Insurance
Division of Corporation Finance
Securities and Exchange
8-K
EX-99.1
m1wb3q fc
13 Feb 20
Avenue Therapeutics Announces New Drug Application for IV Tramadol Accepted for Review by FDA
9:15am
8-K
EX-99.1
2uzal
30 Mar 20
Avenue Therapeutics Reports Full Year 2019 Financial Results and Recent Corporate Highlights
9:01am
10-K
71xxib
1 Mar 18
Annual report
12:00am
10-Q
0x9w0sukblulj7yov
12 May 17
Quarterly report
12:00am
8-K
EX-10.12
qoo3yw2f2wsapzw9y
11 Feb 19
Entry into a Material Definitive Agreement
8:39am